Retinal AI for NAFLD
Non‑alcoholic fatty liver disease risk assessment
Research/Pre‑clinicalActive
Key Facts
Indication
Non‑alcoholic fatty liver disease risk assessment
Phase
Research/Pre‑clinical
Status
Active
Company
About Mediwhale
AI‑powered retinal imaging platform for early cardiometabolic disease risk assessment and eye‑disease diagnosis.
View full company profile